Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

High frequency of SEN virus infection in thalassemic patients and healthy blood donors in Iran

Authors: Abbas Karimi-Rastehkenari, Majid Bouzari

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

SEN virus is a blood-borne, circular ssDNA virus and possessing nine genotypes (A to I). Among nine genotypes, SENV-D and SENV-H genotypes have the strong link with patients with unknown (none-A to E) hepatitis infections. Infection with blood-borne viruses is the second important cause of death in thalassemic patients. The aim of this study was to determine the frequency of SENV-D and SENV-H genotypes viremia by performing nested-PCR in 120 and 100 sera from healthy blood donors and thalassemic patients in Guilan Province, North of Iran respectively. Also, to explicate a possible role of SEN virus in liver disease and established changes in blood factors, the serum aminotransferases (ALT and AST) and some of the blood factors were measured.

Results

Frequency of SENV-D, SENV (SENV-H or SENV-D) and co-infection (both SENV-D and SENV-H) viremia was significantly higher among thalassemic patients than healthy individuals. Frequency of SENV-H viremia was significantly higher than SENV-D among healthy individuals. In comparison to SENV-D negative patients, the mean of mean corpuscular hemoglobin was significantly higher in SENV-D positive and co-infection cases (P < 0.05). The means of AST and ALT were significantly higher in thalassemic patients than healthy blood donors, but there were not any significant differences in the means of the liver levels between SENV-positive and -negative individuals in healthy blood donors and thalassemic patients. High nucleotide homology observed among PCR amplicon's sequences in healthy blood donors and thalassemic patients.

Conclusions

The high rate of co-infection shows that different genotypes of SENV have no negative effects on each other. The high frequency of SENV infection among thalassemic patients suggests blood transfusion as main route of transmission. High frequency of SENV infection in healthy individuals indicates that other routes rather than blood transfusion also are important. Frequency of 90.8% of SENV infection among healthy blood donors as well as high nucleotide homology of sequenced amplicons between two groups can probably suggest that healthy blood donors infected by SENV act partly as a source of SENV transmission to the thalassemic patients. In conclusion, SENV-D isolate in Guilan Province may be having a pathogenic agent for thalassemic patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Primi D, Fiordalisi G, Mantero GL, Mattioli S, Sottini A, Bonelli F: Identification of SENV genotypes. International patent number WO0028039 2000. (international application published under the patent cooperation treaty) [http://ep.espacenet.com/] Primi D, Fiordalisi G, Mantero GL, Mattioli S, Sottini A, Bonelli F: Identification of SENV genotypes. International patent number WO0028039 2000. (international application published under the patent cooperation treaty) [http://​ep.​espacenet.​com/​]
2.
go back to reference Tanaka Y, Primi D, Wang RYH, Umemura T, Yeo AET, Mizokami M, Alter HJ, Shih JW: Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. J Infect Dis 2001, 183: 359-367. 10.1086/318091PubMedCrossRef Tanaka Y, Primi D, Wang RYH, Umemura T, Yeo AET, Mizokami M, Alter HJ, Shih JW: Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. J Infect Dis 2001, 183: 359-367. 10.1086/318091PubMedCrossRef
3.
go back to reference Umemura T, Tanaka Y, Kiyosawa K, Alter HJ, Shih JW: Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus). FEBS Lett 2002, 510: 171-174. 10.1016/S0014-5793(01)03258-6PubMedCrossRef Umemura T, Tanaka Y, Kiyosawa K, Alter HJ, Shih JW: Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus). FEBS Lett 2002, 510: 171-174. 10.1016/S0014-5793(01)03258-6PubMedCrossRef
4.
go back to reference Kojima H, Kaita KDE, Zhang M, Giulivi A, Minuk GY: Genomic analysis of a recently identified virus (SEN virus) and genotypes D and H by polymerase chain reaction. Antiviral Res 2003, 60: 27-33. 10.1016/S0166-3542(03)00133-5PubMedCrossRef Kojima H, Kaita KDE, Zhang M, Giulivi A, Minuk GY: Genomic analysis of a recently identified virus (SEN virus) and genotypes D and H by polymerase chain reaction. Antiviral Res 2003, 60: 27-33. 10.1016/S0166-3542(03)00133-5PubMedCrossRef
5.
go back to reference Umemura T, Yeo AE, Sottini A, Moratto D, Tanaka Y, Wang RY, Shih JW, Donahue P, Primi D, Alter HJ: SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001, 33: 1303-1311. 10.1053/jhep.2001.24268PubMedCrossRef Umemura T, Yeo AE, Sottini A, Moratto D, Tanaka Y, Wang RY, Shih JW, Donahue P, Primi D, Alter HJ: SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001, 33: 1303-1311. 10.1053/jhep.2001.24268PubMedCrossRef
6.
go back to reference Sagir A, Kirschberg O, Heintges T, Erhardt A, Haüssinger D: SEN virus infection. Rev Med Virol 2004, 14: 141-148. 10.1002/rmv.421PubMedCrossRef Sagir A, Kirschberg O, Heintges T, Erhardt A, Haüssinger D: SEN virus infection. Rev Med Virol 2004, 14: 141-148. 10.1002/rmv.421PubMedCrossRef
7.
go back to reference Rady MS, Baffico M, Khalifa AS, Heshmat NM, el-Moselhy S, Sciarratta GV, Hussein IR, Temtamy SA, Romeo G: Identification of Mediterranean beta-thalassemia mutations by reverse dot-blot in Italians and Egyptians. Hemoglobin 1997, 1: 59-69. 10.3109/03630269708997511CrossRef Rady MS, Baffico M, Khalifa AS, Heshmat NM, el-Moselhy S, Sciarratta GV, Hussein IR, Temtamy SA, Romeo G: Identification of Mediterranean beta-thalassemia mutations by reverse dot-blot in Italians and Egyptians. Hemoglobin 1997, 1: 59-69. 10.3109/03630269708997511CrossRef
8.
go back to reference Ventoa S, Cainelli F, Cesario F: Infections and thalassaemia. Lancet Infect Dis 2006, 6: 226-233. 10.1016/S1473-3099(06)70437-6CrossRef Ventoa S, Cainelli F, Cesario F: Infections and thalassaemia. Lancet Infect Dis 2006, 6: 226-233. 10.1016/S1473-3099(06)70437-6CrossRef
9.
go back to reference Mirmomen S, Alavian SM: Treatment of HCV infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response? Hepatitis Monthly 2005, 5: 11-13. Mirmomen S, Alavian SM: Treatment of HCV infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response? Hepatitis Monthly 2005, 5: 11-13.
10.
go back to reference Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24: 1596-1599. 10.1093/molbev/msm092PubMedCrossRef Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24: 1596-1599. 10.1093/molbev/msm092PubMedCrossRef
11.
go back to reference Shibata M, Wang RY, Yoshiba M, Shih JW, Alter HJ, Mitamura K: The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. J Infect Dis 2001, 184: 400-404. 10.1086/322050PubMedCrossRef Shibata M, Wang RY, Yoshiba M, Shih JW, Alter HJ, Mitamura K: The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. J Infect Dis 2001, 184: 400-404. 10.1086/322050PubMedCrossRef
12.
go back to reference Kao JH, Chen W, Chen PJ, Lai MY, Chen DS: Prevalence and implication of a newly identified infectious agent (SEN virus) in Taiwan. J Infect Dis 2002, 185: 389-392. 10.1086/338472PubMedCrossRef Kao JH, Chen W, Chen PJ, Lai MY, Chen DS: Prevalence and implication of a newly identified infectious agent (SEN virus) in Taiwan. J Infect Dis 2002, 185: 389-392. 10.1086/338472PubMedCrossRef
13.
go back to reference Tangkijvanich P, Theamboonlers A, Sriponthong M, Thong-Ngam D, Kullavanijaya P, Poovorawan Y: SEN virus infection in patients with chronic liver disease and hepatocellular carcinoma in Thailand. J Gastroenterol 2003, 38: 142-148. 10.1007/s005350300023PubMedCrossRef Tangkijvanich P, Theamboonlers A, Sriponthong M, Thong-Ngam D, Kullavanijaya P, Poovorawan Y: SEN virus infection in patients with chronic liver disease and hepatocellular carcinoma in Thailand. J Gastroenterol 2003, 38: 142-148. 10.1007/s005350300023PubMedCrossRef
14.
go back to reference Schröter M, Laufs R, Zöllner B, Knodler B, Schafer P, Sterneck M, Fischer L, Feucht H: Prevalence of SENV-H viraemia among healthy subjects and individuals at risk for parenterally transmitted diseases in Germany. J Viral Hepat 2002, 9: 455-459. 10.1046/j.1365-2893.2002.00390.xPubMedCrossRef Schröter M, Laufs R, Zöllner B, Knodler B, Schafer P, Sterneck M, Fischer L, Feucht H: Prevalence of SENV-H viraemia among healthy subjects and individuals at risk for parenterally transmitted diseases in Germany. J Viral Hepat 2002, 9: 455-459. 10.1046/j.1365-2893.2002.00390.xPubMedCrossRef
15.
go back to reference Pirovano S, Bellinzoni M, Matteelli A, Ballerini C, Albertini A, Imberti L: High prevalence of a variant of SEN-V in intravenous drug user HIV-infected patients. J Med Virol 2002, 68: 18-23. 10.1002/jmv.10165PubMedCrossRef Pirovano S, Bellinzoni M, Matteelli A, Ballerini C, Albertini A, Imberti L: High prevalence of a variant of SEN-V in intravenous drug user HIV-infected patients. J Med Virol 2002, 68: 18-23. 10.1002/jmv.10165PubMedCrossRef
16.
go back to reference Yoshida H, Kato N, Shiratori Y, Shao R, Wang Y, Shiina S, Omata M: Weak association between SEN virus viremia and liver disease. J Clin Microbiol 2002, 40: 3140-3145. 10.1128/JCM.40.9.3140-3145.2002PubMedPubMedCentralCrossRef Yoshida H, Kato N, Shiratori Y, Shao R, Wang Y, Shiina S, Omata M: Weak association between SEN virus viremia and liver disease. J Clin Microbiol 2002, 40: 3140-3145. 10.1128/JCM.40.9.3140-3145.2002PubMedPubMedCentralCrossRef
17.
go back to reference Akiba J, Umemura T, Alter HJ, Kojiro M, Tabor E: SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion 2005, 45: 1084-1088. 10.1111/j.1537-2995.2004.00209.xPubMedCrossRef Akiba J, Umemura T, Alter HJ, Kojiro M, Tabor E: SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion 2005, 45: 1084-1088. 10.1111/j.1537-2995.2004.00209.xPubMedCrossRef
18.
go back to reference Pfeiffer RM, Tanaka Y, Yeo AE, Umemura T, Seal KH, Shih JW, Alter HJ, Edlin BR, O'Brien TR: Prevalence of SEN viruses among injection drug users in the San Francisco bay area. J Infec Dis 2003, 188: 13-18. 10.1086/375740CrossRef Pfeiffer RM, Tanaka Y, Yeo AE, Umemura T, Seal KH, Shih JW, Alter HJ, Edlin BR, O'Brien TR: Prevalence of SEN viruses among injection drug users in the San Francisco bay area. J Infec Dis 2003, 188: 13-18. 10.1086/375740CrossRef
19.
go back to reference Sharifi Z, Mahmoodian-Shooshtari M, Talebian A: The prevalence of SEN virus infection in blood donors in Iran. Arch Iran Med 2008, 11: 423-426.PubMed Sharifi Z, Mahmoodian-Shooshtari M, Talebian A: The prevalence of SEN virus infection in blood donors in Iran. Arch Iran Med 2008, 11: 423-426.PubMed
20.
go back to reference Umemura T, Alter HJ, Tanaka E, Orii K, Yeo AE, Shih JW, Matsumoto A, Yoshizawa K, Kiyosawa K: SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology 2002, 35: 953-959. 10.1053/jhep.2002.32536PubMedCrossRef Umemura T, Alter HJ, Tanaka E, Orii K, Yeo AE, Shih JW, Matsumoto A, Yoshizawa K, Kiyosawa K: SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology 2002, 35: 953-959. 10.1053/jhep.2002.32536PubMedCrossRef
21.
go back to reference Kao JH, Chen W, Chen PJ, Lai MY, Chen DS: SEN virus infection in patients with chronic hepatitis C: preferential co-infection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin. J Infect Dis 2003, 187: 307-310. 10.1086/346055PubMedCrossRef Kao JH, Chen W, Chen PJ, Lai MY, Chen DS: SEN virus infection in patients with chronic hepatitis C: preferential co-infection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin. J Infect Dis 2003, 187: 307-310. 10.1086/346055PubMedCrossRef
22.
go back to reference Lin JG, Goto T, Nakane K, Miura K, Mikami KI, Ohshima S, Yoneyama K, Watanabe S: Clinical significance of SEN-virus on interferon response in chronic hepatitis C patients. J Gastroenterol Hepatol 2003, 18: 1144-1149. 10.1046/j.1440-1746.2003.02946.xPubMedCrossRef Lin JG, Goto T, Nakane K, Miura K, Mikami KI, Ohshima S, Yoneyama K, Watanabe S: Clinical significance of SEN-virus on interferon response in chronic hepatitis C patients. J Gastroenterol Hepatol 2003, 18: 1144-1149. 10.1046/j.1440-1746.2003.02946.xPubMedCrossRef
23.
go back to reference Pirovano S, Bellinzoni M, Ballerini C, Cariani E, Duse M, Albertini A, Imberti L: Transmission of SEN virus from mothers to their babies. J Med Virol 2002, 66: 421-427. 10.1002/jmv.2162PubMedCrossRef Pirovano S, Bellinzoni M, Ballerini C, Cariani E, Duse M, Albertini A, Imberti L: Transmission of SEN virus from mothers to their babies. J Med Virol 2002, 66: 421-427. 10.1002/jmv.2162PubMedCrossRef
24.
go back to reference Moriondo M, Resti M, Betti L, Indolfi G, Poggi GM, de-Martino M, Vierucci A, Azzari C: SEN virus co-infection among HCV-RNA-positive mothers, risk of transmission to the offspring and outcome of child infection during a 1-year follow-up. J Viral Hepat 2007, 14: 355-359. 10.1111/j.1365-2893.2006.00805.xPubMedCrossRef Moriondo M, Resti M, Betti L, Indolfi G, Poggi GM, de-Martino M, Vierucci A, Azzari C: SEN virus co-infection among HCV-RNA-positive mothers, risk of transmission to the offspring and outcome of child infection during a 1-year follow-up. J Viral Hepat 2007, 14: 355-359. 10.1111/j.1365-2893.2006.00805.xPubMedCrossRef
25.
go back to reference Serin MS, Koksal F, Oksuz M, Abayli B, Aslan G, Tezcan S, Yildiz C, Kayar B, Emekdas G: SEN virus prevalence among non-B and non-C hepatitis patients with high liver function tests in the south of Turkey. Jpn J Infect Dis 2005, 58: 349-352.PubMed Serin MS, Koksal F, Oksuz M, Abayli B, Aslan G, Tezcan S, Yildiz C, Kayar B, Emekdas G: SEN virus prevalence among non-B and non-C hepatitis patients with high liver function tests in the south of Turkey. Jpn J Infect Dis 2005, 58: 349-352.PubMed
26.
go back to reference Sagir A, Adams O, Antakyali M, Oette M, Erhardt A, Heintges T, Haussinger D: SEN virus has an adverse effect on the survival of HIV-positive patients. AIDS 2005, 19: 1091-1096. 10.1097/01.aids.0000174456.08992.2bPubMedCrossRef Sagir A, Adams O, Antakyali M, Oette M, Erhardt A, Heintges T, Haussinger D: SEN virus has an adverse effect on the survival of HIV-positive patients. AIDS 2005, 19: 1091-1096. 10.1097/01.aids.0000174456.08992.2bPubMedCrossRef
Metadata
Title
High frequency of SEN virus infection in thalassemic patients and healthy blood donors in Iran
Authors
Abbas Karimi-Rastehkenari
Majid Bouzari
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-1

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.